EURO DURG bulletin

No. 10 November 2000

EUROPEAN DRUG UTILIZATION RESEARCH GROUP

Editors. This issue was prepared by the following members of the Executive Committee of EURO DURG: Morten Andersen.

Strategy for the realisation of the general objectives of “Mapping Europe”

EURO DURG has advocated since its inception, the use of validated scientific methods to construct monitor systems for drug utilization in the European countries:

• To be able to study drug utilization from the double perspective of cost and volume in a population-based approach, EURO DURG recommended the general use of the Anatomical Therapeutic Chemical Classification (ATC) and the Defined Daily Dose (DDD).

• EURO DURG has sustained the ongoing activities of the WHO-Collaborating Centre for Drugs Statistics Methodology in Oslo, to maintain and expand the ATC classification and DDD methodology, now under supervision of WHO at world level.

• EURO DURG scientists participated actively in a number of countries in the actual creation and maintenance of national monitoring systems, particularly in the northern countries and the Central and Eastern countries of Europe.

• EURO DURG has welcomed the initiatives of the European Commission for concerted action to create internationally validated national monitoring systems for antibiotics utilization, in response to the Copenhagen Recommendations, issued at the 1998 EU conference on the microbial treat.

Moreover, a similar observation can be made in the different projects regarding drug information, tracking of drug regulatory activities, drug price policy and drug utilization monitoring at the European level.

The strategic decision was therefore to take two initiatives:

1. To collect, in an exemplary way, data on antibiotics (project described in EURO DURG bulletin No. 9).

2. To propose a number of European projects in the Research programs of the European Commission.

These research projects pertain to the technological aspects (health telematics) of creating a European Database of registered and marketed Medicinal Products, to the implementation of the European Standard of Medicinal Product Identification of the CEN (European Committee for Normalisation), and to validated linkage procedures of unique identifiers of medicinal products on the national market to the internationally accepted classification systems (i.e. ATC).

Furthermore, the creation of this database is linked to a proposal for technical excellence in bringing independent drug information to physicians and patients, in cooperation with the national drug information centres and the competent national authorities.

One of these projects (MEPIRA) is already formally submitted in a consortium with Prof. G. Demoor (Health Informatics, Ramit), WHO-EURO, and an information technology company.

Granting of this project would make it possible to create a trans European network to validate and field test the structural specifications of a European database of Medicinal products, and to elaborate the functional analysis of a database maintenance tool for national authorities and national drug information centres.

R. Vander Stichele, B-DURG

Visit the EURO DURG web site http://www.eurodurg.org

IN THIS ISSUE

- Strategy for “Mapping Europe” p. 1
- Report from the EURO DURG General Assembly p. 2
- ISPE/EURO DURG joint sessions in Barcelona p. 3
- EURO DURG Executive Committee p. 4
- EURO DURG meeting. Prague 2001 p. 4
- EURO DURG/EACPT joint sessions, Odense 2001 p. 4
- Challenges in drug utilisation research – Karl Kimbel in memoriam p. 5
- Update on National DURGs in Europe p. 6
EURODURG website is still active even if there have been problems with the updates.

"The way ahead", a discussion document for general policy of EURODURG, has been prepared by the executive committee. This document was distributed to all national chairs in June.

Financial report

Emilio Sanz briefly presented the financial report for the period 1998-2000.

Report from the working groups

Emilio Sanz presented a brief report from two of the EURODURG working groups:
- TUPP – The User Perspective Project
- CHILDURG – Childrens use of Medications Study
Further information about these groups are available in EURODURG bulletin no 9

Robert Vander Stichele reported from the "Mapping Europe" project. A document explaining the strategy for the realisation of the general objectives of "Mapping Europe" is included elsewhere in this bulletin.

Hege Salvesen Blix reported from the collection of drug utilisation data on antibacterials. A brief outline of this project was presented in EURODURG bulletin no 9.

Reports of national DURGs

Svetlana Ratchina gave a presentation of the latest formalised national group, DURG Russia or the Russian Society of Pharmacoepidemiology.

There was no time for reports from other national groups.

"The way ahead"

The policy document was briefly discussed. It was concluded that the discussion should be continued in the national groups and that the executive committee should try to prepare some general policy "guidelines" in the next period, based on input from the members.

Future meetings

A separate EURODURG meeting will be arranged 7-10 June 2001 in Prague.

A joint EURODURG/EACPT symposium will be arranged in Odense in September 2001.

Election of the EURODURG executive committee 2000-2002

The nominating committee consisting of Annemarie Hoffmann (Germany), Ebba Holme Hansen (Denmark) and Nicola Montanaro (Italy) had received 13 candidates for the new executive committee (see EURODURG bulletin no. 9).

Votes were received from 11 countries.

The following eleven candidates were elected for the EURODURG executive committee 2000-2002:

John Ferguson - UK (chair)
Monique Elseviers - Belgium (new)
Karel Nemec - Czech Republic (new)
Morten Andersen - Denmark
Joerg Hasford - Germany
Gyöngyvér Soós - Hungary (new)
Almar Grimsson - Iceland
Marit Rønning - Norway
Alfonso Carvajal García-Pando - Spain (new)
Christer Luthman - Sweden (new)
Lołkke T.W. de Jong-van den Berg - The Netherlands (new)

Election of nominating committee 2002

The following candidates for the new nominating committee were elected:

Flora Haaijer-Ruskamp - The Netherlands
Robert Vander Stichele - Belgium
Ulf Bergman - Sweden

Closing remarks

The new chair, John Ferguson, welcomed the new members of the Executive Committee and thanked the former members of Executive Committee for the passed years. Special thanks were given to the former chair, Flora Haaijer-Ruskamp, for her strong commitment in building up the EURODURG as a scientific association.

Marit Rønning
During the joint meeting of EURO DURG and ICPE on Monday 21st August in Barcelona there were two sessions with the issue: Drug use and Prescribing practice.

Morning session

During the first session on Monday-morning there were 6 presentations of which three regarding drug compliance and adherence.

The study of Peter Donnan from the University of Dundee was about adherence to prescribed oral hypoglycaemic medications. He concluded that one in three patients with type 2 diabetes had adequate adherence to their medications. One daily dosing and a lower number of comediations were associated with better adherence.

A study presented by Philip S. Wang of the Harvard Medical School identified factors, including modifiable psychosocial and behavioural characteristics of patients, associated with poor adherence with antihypertensive therapy. He concluded that depressive symptoms may be an underrecognized but modifiable risk factor for poor antihypertensive compliance. Patient knowledge of hypertension, health beliefs, and poor psychosocial variables do not appear to consistently affect adherence.

Yola Moride from the Faculty of Pharmacy of the Montreal University presented her study of predictors of adherence to antidepressive treatment. She evaluated whether the recommended at least 6 months treatment was maintained in a fixed cohort of 1301 GP’s and 236 psychiatrists. She found that only 55% of treatments initiated by GP’s were more than 6 months versus 73% for psychiatrists. Factors that significantly decreased adherence were among others urban practice, age of the patient and increasing co-morbidity. She concluded that since patients who initiate treatment from GP’s are less likely to follow guidelines, interventions should be targeted towards GP’s especially in urban regions.

All these studies looked at factors influencing compliance and these findings are important for those who are planning interventions to improve drug compliance in every day medical and pharmaceutical practice.

Lolijke T. W. de Jong-van den Berg

Afternoon Session

Several of the afternoon presentations dealt indirectly with the problem of accessing knowledge at the right time. We have a lot of knowledge of how to treat and how to use the pharmacological toolbox, but sometimes there seems to be a discrepancy between evidence based medicine and the everyday reality, exemplified during the afternoon. The reason for this discrepancy might have to do with a lack of coordination of medical and pharmaceutical information and perhaps also a lack of feedback to the prescriber. If this is the case, treatment, outcome and adverse effects should be properly recorded and accessible in the right situation to the benefit for the patient. A task for the future would be to agree upon a minimum level of an infrastructure for informatics within the healthcare systems. So, in the glorious tomorrow the patient will not be a hazard to an otherwise perfect health care system.

In the first presentation the striking difference in therapeutic tradition between Denmark and Italy of antibiotic use in children was shown. In Italy the broad-spectrum antibiotics are dominating whereas in Denmark the narrow-spectrum penicillins and macrolides are. The big difference in resistance patterns, the most severe one in Italy, was also illustrated. In Denmark, however, antibiotic resistant pneumococci are still extremely rare.

The second presentation showed that in the UK, contrary to the therapeutic guidelines, the use of combined oral contraceptives did not decrease among women with the diagnosis lupus erythematosus (SLE).

The third presentation illustrated a positive result, how the use of newer and more efficient pharmaceuticals for treating early symptoms of lower urinary tract symptoms (LUTS) now postpones surgery. The postponement of surgery was associated with earlier treatment and the increase of use of newer, more effective products such as finasteride and new alfa-blockers. At this point of the afternoon it felt releaving to hear how knowledge can be used to the benefit for the patients.

In the fourth presentation we were told about the use of contraindicated drugs, in this case NSAIDs, to people with previously proved gastrointestinal problems. But during the discussion it became clear that ASA was used in low dosage as an antithrombotic agent.

The fifth presentation was from Denmark and described the influence of risk factors, as day care attendance, on use of systemic antibiotics in kids. The conclusion was that there are no difference in risk for the kids between these forms of day care for receiving systemic antibiotics – at least not in the studied age group 0-2 years old. A conclusion, though not so well documented, was that a longer maternity leave would decrease the use of antibiotics. This is a very important socio-economical point.

The sixth presentation "Patterns of Hormone Replacement Therapy in the UK" with focus on women with and without hysterectomy. The adherence is 88% which is high in comparison to other drug groups. A substantial proportion of women still receive unopposed estrogens; they should also receive prostagens to reduce their risk of endometrial cancer.

The last presentation of the afternoon was about the "High Failure Rates of Presumptive Helicobacter Eradication Therapy in General Practice". A prescription database in Ireland was used to determine success rates. They found a 56% failure rate and even higher in the age group over 65. This is over 5 times the reported failure rate in controlled hospital-based trials. This seemed as a consequence of bias, because the outcome measure was inappropriate.

Christer Luthman
Gyöngyvér Soós

Results of poster evaluation

First authors and titles of posters awarded in the ISPE/EURO DURG poster sessions are listed.

1st prize: Nana Thrane. Individual use of antibiotics and prevalence of beta-lactam resistance among bacterial pathogens from middle ear fluid.
2nd prize: Lisa G. Pont. Asthma and asthma medication – a database study of asthma treatment in general practice.

3rd prize: Fabrizio de Ponti. Exposure to non-cardiac QT-prolonging drugs in the community – comparison among seven countries.

Awards for each session:
- E. Soler Company. Patterns of analgesic drugs utilization during the postoperative period in a Spanish hospital.
- Jose C. Domingues. Therapeutic profile of antihypertensive drug use by Portuguese sentinel GP.
- Lars Bjerrum. Increasing prescription rate of lipid lowering drugs after introduction of guidelines on cardiovascular risk.
- Jens-Ulrik Rosholm. Use of antidepressants from 1992 to 1997 with focus on duration of treatment and age-related prevalence.
- Kirsten Schaefer. Psychopharmacology and general practice. A quality improvement project in the County of Roskilde, Denmark.
- Björn Beermann. Prescription based study on the use of orlistat.
- Lisa G. Pont. Relevance of interventions to reduce polypharmacy.

EURO DURG meeting, Prague, Czech Republic 7-10 June 2001
Integrating drug utilization studies in a wider Europe
Venue: State Institute of Drug Control

A central issue of the meeting is the construction of a European data base with information on pharmaceuticals, and tools for editing and disseminating independent information on medicines to health professionals, patients and the lay public at the national level. We will also focus on the topics of health technology assessment, meta-analysis, drug information, guideline development, promotion of rational drug use, drug classification, implementation of research and the effect of pharmacovigilance findings on the decision process guiding drug prescribing and drug taking.

http://congress.cls.cz/eurodurg/

EURO DURG Executive Committee

Chair
Dr. John Ferguson (United Kingdom)*

Secretary
Marit Rønning (Norway)*

Treasurer
Dr. Morten Andersen (Denmark)*

Members
Prof. Alfonso Carvajal García-Pando (Spain)
Tel: +34 983263021
Fax: +34 983423022
e-mail: carvajal@ife.uva.es

Monique Elseviers (Belgium)
Tel: +32 38213406
Fax: +32 38290100
e-mail: elsevier@uia.ua.ac.be

Dr. Almar Grimsson (Iceland)*

Prof. Joerg Hasford (Germany)*

Lolkje T.W. de Jong-van den Berg (the Netherlands)
Tel: +31 503637576
Fax: +31 503632772
e-mail: lolkke@farm.rug.nl

Karel Nemecek (Czech Republic)
Tel: +420 221107285
Fax: +420 221107160
e-mail: karel.nemecek@op99.vzp.cz

Christr Luthman (Sweden)
Tel: +46 706637786
Fax: +46 44122101
e-mail: christr.luthman@apoteket.se

Gyöngyvér Soós (Hungary)

EURO DURG joint sessions on 14-15 September.

Session A.3 - Drug use in the paediatric population in Europe

Chair: E. Sanz (Spain)
Co-chair: G. Pons (France)

1. Drug use research in children. The project CHILDURG (E. Sanz, Spain)

2. Drug use in children in Eastern Europe (S. Rachina, Russia)

3. Drug use in children in EU (A. Peiré, Spain)

4. The use of population databases to explore the use of drugs by children (J. Straand, Norway)

5. Qualitative studies on drug use in children: what do children think about health, disease and the use of medicines. A multidisciplinary, cross-cultural research to study drug use. The COMAC and ASPSRO1 and ASPSRO2 projects (D. Trakas, Greece)

Session A.4 - Quality indicators in drug use

Chair: M. Andersen (Denmark)
Co-chair: N. Montanaro (Italy)

1. How to implement general indicators for the quality of drug use in clinical practice (U. Bergman, Sweden)

2. Poor quality of drug treatment observed in patients entering the clinical trials in cardiology (P. Lechat, France)

3. Measuring changes in quality of drug use in intervention studies (M. Maclure, Canada)

4. Quality aspects in NSAID use (J.R. Laporte, Spain)

5. Indicators for the quality of asthma treatment (P. Denig, L. Pont, Netherlands)

http://www.sdu.dk/med/homepages/eacpt/eacpt5.html

*Tel, fax and e-mail on page 6.
The Contergan (thalidomide) catastrophe required an explanation free from the specific interests of the pharmaceutical industry and demanded methodically reliable and scientifically independent studies into medication risks, in particular after admission to the market. As the Contergan experience showed, there are severe risks that then become obvious only when the drug is used in outpatient care. These considerations motivated the constitution of the Drug Utilisation Research Group (DURG) at the European WHO Office (1964). The founding members came from those countries whose health system is organized nation wide. In these countries, which include Great Britain, Germany and its Nordic neighbors, the well-being of the citizens has priority to commercial interests. These countries have data for their health systems at their disposal which form a suitable basis for drug utilization research. The first drug utilization studies that became models for this kind of research were published in the Nordic countries [Baksaas 1980, Gross and Inman 1977].

In 1996 the EURO DURG was established as an independent society in Balaton, Hungary and as the umbrella organization for all the national societies. The “Gesellschaft für Arzneimittelanwendungsforschung (GAA)” (Society for Drug Utilization Research) was one of the co-founders.

Already in 1992 Karl Kimbel had taken the initiative in founding the GAA. In its constitution the Society defined the following aims and tasks: It supports scientific research into the utilization of drugs; in particular, it is concerned with the influences on drug use and prescribing behavior and the study of benefits and risks of drug therapy. It is engaged in the distribution of research results. It supports international cooperation in these fields.

In setting these aims the GAA adopts an important position – as a Public Health Discipline – in relation to pharmacoepidemiology whose focal point lies in research into the effects and side-effects of drugs, primarily in clinical studies.

Karl Kimbel thought the following questions should guide the research activities of the EURO DURG:
- What evidence-based information is available concerning medication and drug utilization?
- What characterizes medication used by the patient, what characterizes drug utilization by the doctor?
- Do medication and drug utilization meet quality criteria?

In his opinion, the results of such studies, should form the basis for research in the following context:
- Which social, mental and cultural patterns influence the patients’ demand and put prescribing pressure on the doctor?
- Can medically necessary drug use be separated from medically unnecessary use? If so, how can the dividing line be set in a practical manner?
- Which contraindications against the use of particular drugs must be considered? For example, interactions, ADR, introduction of new drugs without sufficient experience.

The database used to examine these questions should be, according to Kimbel, the implementation of documents from statutory health insurance or state-financed health care, as is the case in the Nordic countries, Great Britain, Canada and Italy. In Germany the statutory health insurance (GKV) data is most suitable. Such data are a reliable basis for epidemiological statistics concerning mortality, morbidity and care, if they can be made widely available and be analyzed both on a population and on an individual level. These data are then particularly suitable for drug utilization research.

Just last year Karl Kimbel intensified his efforts in public statements to resume research on a random sample of insured persons in the GKV. He engaged in the campaign promoting patient-related research within the limits set by the data protection laws.

Likewise he was involved in the demand for the unrestricted publication of the Drug Prescribing Report 1997 (Arznei-Verordnungs-Report 1997) against legal objections of the pharmaceutical industry. Kimbel’s aim was to provide a neutral ground for uncensored drug reports.

Karl Kimbel regarded close cooperation of national and European research as important. Joint projects which must be borne in mind are: the Mapping Europe project – an international comparison of drug use in Europe, Kimbel made an effort to establish an internationally defined daily dose (DDD) and ATC (WHO drug coding system), used commonly in all participating countries, as a technical prerequisite for international drug utilization research.

With respect to quality assurance and optimization of drug therapy Kimbel was convinced that it is hard to determine the dividing lines between necessary and unnecessary use which are not clear, above all, to the general practitioner. Therefore, he regarded the definition of “necessary” and “unnecessary use” as the most crucial problem for research, since the GP urgently needs this information for everyday prescribing.

All of us who work in the field of drug utilization research are very thankful to Karl Kimbel for having laid the most important milestone for our research. We can best show our appreciation by putting his ideas into practice.

PD Dr. med. L. von Ferber  
Primary Health Care Research Unit  
Universität Köln, Germany
An update of National DURGs in Europe

Chairs and/or contact persons also to be found on our web page: http://www.eurodurg.org

ARMENIA: DURG-Armenia
Dr. Irina Kazarian
Department of Pharmacy, National Institute of Health
49/4 Komitas Avenue
Yerevan, 375051, Republic of Armenia
Tel: +374 2 227247; fax: +374 3907216
email: ioannis@1x2.yerphi.am

BELGIUM: B-DURG
Denise Walckiers, pharmacist
Scientific Institute of Public Health – Louis Pasteur
Rue Wysman, 14
B-1050 Bruxelles, Belgium
Tel: +32 2 642 5035; fax: +32 2 642 5410
e-mail: denise.walckiers@iph.fgov.be

BULGARIA: DURG-Bulgaria
Dr. Zlatka Dimitrova
Medical University – Sofia, Faculty of Pharmacy
2 Dunav Street
Sofia 1000, Bulgaria
Tel: +359 2 98026; fax: +359 2 9874
e-mail: zdimitrova@mbox.pharmfac.acad.bg

CZECH REPUBLIC: Czech-DURG
Dr. Vladimir Biba
State Institute for Drug Control - SUKL,
Srobarova 48
100 41 Prague 10, Czech Republic
Tel: +420 2 6708 2890; fax: +420 2 744 977
email: zdimitrova@mbox.pharmfac.acad.bg

DENMARK: The Danish Society for Pharmacoepidemiology
Dr. Morten Andersen
Clinical Pharmacology, University of Southern Denmark
Winsløwparken 19
DK-5000 Odense C, Denmark
Tel: +45 6550 3791; fax: +45 6591 6089
e-mail: m-andersen@ckfo.sdu.dk

GERMANY: Gesellschaft für Arzneimittelwendungsforschung und Arzneimittel-epidemiologie (GAA) e.V.
Prof. Joerg Hasford
Pharmacoepidemiology Research Group, Department of IBE
Ludwig-Maximilians-University
D-81377 Munich, Germany
Tel: +49 89 709 57480 fax: +49 89 709 57482
email: has@ibe.med.uni-muenchen.de

GREECE: DURG GR
Dr. A. Biopoulou
Section of Clinical Pharmacology, Dept. of Clinical Therapeutics,
Athens University, Alexander Hospital
80 Vas Sofias Str.
115 28 Athens, Greece
Tel+fax: +30 1 7771 731
e-mail: alliot@atlas.oua.gr

HUNGARY: DURG-Hungary
Dr. Zsuzsanna Szepedzi
National Institute of Pharmacy
Zrínyi u.3., H-1372 Budapest, Hungary
Tel: +36 1 317 7113; fax: +36 1 318 1167
e-mail: szepedzi@ogyi.hu

ICELAND: IS DURG
Almar Grimsson
Háahvammi 7
IS-220 Hafnarfjördur, Iceland
Tel:+354 555 2098; fax:+354 555 3561
e-mail: albas@itn.is

ISRAEL: ISRAEL DURG
Prof. Micha Levy, MD
Dept. of Medicine
Hadassah University Hospital
Jerusalem 91-120, Israel
Tel: +972 2 6776 449; fax: +972 2 6422 384
e-mail: rach@hassadah.org.il

ITALY: DURG-Italia
Dr. Alberto Vaccheri
University of Bologna
Department of Pharmacology
Via Inerio 48
I-40126 Bologna, Italy
Tel: +39 51 248526; fax: +39 51 248862
e-mail: vaccheri@biocfarm.unibo.it

NORWAY: DURG NO
Marit Rønning
WHO Collaborating Centre for Drug Statistics Methodology
Sven Ottesdalsvei 10
N-0903 Oslo, Norway
Tel: +47 22 169810; fax: +47 22 169818
e-mail: marit.ronning@nmd.no

RUSSIA
Dr. Svetlana A. Ratchina
State Medical Academy
P.O. Box 5, Smolensk,
214019 Russia
Tel: (0812) 553401; fax: (0812) 550624
e-mail: sveta@cliph.keytown.com

SPAIN: DURG-ESPAÑA
Dr. Emilio Sanz
Clinical Pharmacology Unit, School of Medicine
University of La Laguna
E-38071 La Laguna, Tenerife, Spain
Tel: +34 922 319347; fax: +34 922 655995
e-mail: esanz@ull.es

SWEDEN: The Swedish Society for Pharmacoepidemiology
Dr. Ulf Bergman
Department of Clinical Pharmacology, Karolinska Institutet
Huddinge University Hospital
S-141 86 Huddinge, Sweden
Tel: +46 8 58 58 1196; fax: +46 8 58 58 1070
e-mail: ulf.bergman@pharmlab.hs.sll.se

THE NETHERLANDS: NL-DURG
Dr. R. M. C. Herings
Dept. of Pharmacoepidemiology, Faculty of Pharmacy
University of Utrecht
PO Box 80082
NL-3508 TB Utrecht, The Netherlands
Tel: +31 30 253 7325; fax: +31 30 253 9166
e-mail: r.m.c.herings@far.ruu.nl

UNITED KINGDOM: DURG-UK
Dr. John Ferguson
Prescription Pricing Authority
Bridge House, 152 Pilgrim Street
Newcastle upon Tyne NE1 6SN, UK
Tel: +44 191 2035351; fax: +44 191 2035499
e-mail: john.ferguson@ppa.nhs.uk